Athenex Inc

Athenex — Investor Presentation (January 2021)

26 slides from Athenex's investor presentation, January 2021

  1. Slide 1: Corporate Presentation

    CORPORATE PRESENTATION January 2021 NASDAQ:ATNX www.athenex.com

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements Except for historical information, all of the statements, expectations, and assumptions contained in this presentation constitute forward- looking statements. These statements include descriptions regarding the intent, belief or current expectations of Athenex, Inc. (the “

  3. Slide 3: Global Oncology-Focused Biopharmaceutical Company

    Global Oncology-Focused Biopharmaceutical Company Improving the lives of cancer patients everywhere Late-Stage Oncology • Oral paclitaxel and encequidar for metastatic breast cancer: PDUFA date - Feb. 28, 2021; Priority Review granted Company • Klisyri® (tirbanibulin) for actinic keratosis received

  4. Slide 4: Increasing Importance of Oral Chemotherapy Options

    Increasing Importance of Oral Chemotherapy Options • Consideration of alternative dosing schedule to allow for fewer in-person visits to the cancer center and/or the infusion center • Switch from infusional therapy to oral oncolytics if equivalent formulation is available Source: https://www.nccn.or

  5. Slide 5: Orascovery Platform: Encequidar, a Novel P-gp Pump Inhibitor

    Orascovery Platform: Encequidar, a Novel P-gp Pump Inhibitor Designed to Enable Oral Absorption of Chemotherapy Agents A. Without Encequidar B. With Encequidar P-glycoprotein (P-gp) Encequidar CHEMOTHERAPY BIOAVAILABILITY Drug efflux Drug Many chemotherapies are P-gp substrates, and can only be give

  6. Slide 6: Pharmacokinetic Model of Oral Paclitaxel

    Pharmacokinetic Model of Oral Paclitaxel P-gp Pump Inhibition Resulted in Higher Drug Exposure and Better Tolerability Than IV Oral Paclitaxel 205 mg/m2 QDx3 weekly* vs. IV Paclitaxel 175 mg/m2 Q3W Oral Paclitaxel 205 mg/m2 QDx3 weekly* Plasma paclitaxel concentration (ng/mL) 1 Reduced Cmax = decrea

  7. Slide 7: Phase III Study of Oral Paclitaxel in Metastatic Breast Cancer

    Phase III Study of Oral Paclitaxel in Metastatic Breast Cancer Clinical Trial Designed to Support Registration in the U.S. (Presented at 2019 SABCS) N 2:1 Randomization MBC Patients Eligible for Paclitaxel Oral Paclitaxel + Encequidar (OPE) IV Paclitaxel (IVP) 205 mg/m2 x 3 days weekly1 175 mg/m2 on

  8. Slide 8: Phase III Study of Oral Paclitaxel Met Primary ORR Endpoint

    Phase III Study of Oral Paclitaxel Met Primary ORR Endpoint Statistically Significant Improvement in ORR Compared to IV Paclitaxel (Presented at 2019 SABCS) Confirmed Response Rate Confirmed Response Rate (ITT Population) (Prespecified mITT Population) Δ=12.4% Δ=14.8% p=0.011 p=0.005 40.4% 35.8% 23.

  9. Slide 9: Overall Survival in ITT Population

    Overall Survival in ITT Population (Data cut: September 2020) (Presented at 2020 SABCS) HR=0.794 (95% CI: 0.607, 1.037) P=0.0821 OS, ITT (N=402) Median Estimate, mo Censored Summary, % Patient deaths (events), % OPE (n=265) 22.7 42 58 IVP (n=137) 16.5 35 65 OPE, Oral Paclitaxel Group; IVP, IV Paclit

  10. Slide 10: Progression-Free Survival in ITT Population

    Progression-Free Survival in ITT Population Trend in Favor of Oral Paclitaxel (Data cut: September 2020) (Presented at 2020 SABCS) HR=0.768 (95% CI: 0.584,1.01) P=0.0459 PFS, ITT Median Estimate, mo Censored Summary, % Patients with event1, % (N=402) OPE (n=265) 8.4 43 53 IVP (n=137) 7.4 30 64 OPE,

  11. Slide 11: Overall Survival in Prespecified mITT Population

    Overall Survival in Prespecified mITT Population Demonstrated Survival Benefit (Data cut: September 2020) (Presented at 2020 SABCS) HR=0.735 (95% CI: 0.556, 0.972) P=0.0262 OS, mITT (N=360) Median Estimate, mo Censored Summary, % Patient deaths (events), % OPE (n=235) 23.3 42 58 IVP (n=125) 16.3 33

  12. Slide 12: Progression-Free Survival in Prespecified mITT Population

    Progression-Free Survival in Prespecified mITT Population Trend in Favor of Oral Paclitaxel (Data cut: September 2020) (Presented at 2020 SABCS) HR=0.739 (95% CI: 0.561,0.974) P=0.0229 PFS, mITT (N=360) Median Estimate, mo Censored Summary, % Patients with event1, % OPE (n=235) 8.4 43 57 IVP (n=125)

  13. Slide 13: Treatment-emergent Adverse Events of Interest (TEAEs)

    Treatment-emergent Adverse Events of Interest (TEAEs) Safety Population (N=399) (Presented at 2020 SABCS) Cumulative Risk of Neuropathy Relevant1 with CTCAE Grade >2 Neuropathy TEAEs (% of population) OPE (n=264) IVP (n=135) Neuropathy relevant1 with CTCAE grade >2 8.0% 31.0% Neuropathy relevant1 wi

  14. Slide 14: Market Opportunity for Oral Paclitaxel in MBC in the U.S.

    Market Opportunity for Oral Paclitaxel in MBC in the U.S. Metastatic Breast Cancer Represents 160,000 to 170,000 Patients HER2+ HR+/HER2- TNBC Unknown Incidence Rate: ~14%1 Incidence Rate: ~68%1 Incidence Rate: ~10%1 Incidence Rate: ~8%1 Common regimens Endocrine therapy Oral Paclitaxel and 1L +/- C

  15. Slide 15: Commercial Preparations on Track

    Commercial Preparations on Track MEDICAL AFFAIRS MARKET ACCESS MARKETING SALES ✓ ✓ Launched “Facing Established scientific ✓ Defined trade and ✓ Completed account communication MBC Together” distribution strategy targeting platform campaign ✓ Developed payer ✓ Building data ✓ Key data generation ✓ E

  16. Slide 16: Opportunity to Expand Oral Paclitaxel's Addressable Market

    Opportunity to Expand Oral Paclitaxel’s Addressable Market Potential Addressable US Patients: > 545,000 (US Incidence) 545,000 25,000 42,000 18,000 35,000 149,000 276,000 Early Stage BC Metastatic 70,000 Current Total Breast Metastatic Metastatic Metastatic Metastatic Head Metastatic Addressable Can

  17. Slide 17: Potential Areas of Interest

    Potential Areas of Interest Pursue opportunities Pursue emerging where paclitaxel is combination opportunities standard of care Expanding into indications where Combining with immunotherapies Paclitaxel is SOC Early-stage breast cancer Lung cancer Ovarian cancer Gastroesophageal (GE) cancer Lung can

  18. Slide 18: I-SPY Trial Overview

    I-SPY 2 Trial Overview A Phase II trial designed to screen novel agents in the neoadjuvant setting • Patients are randomized to chemotherapy + / - a novel agent • Endpoint is pathologic complete response (pCR) • Graduation: 85% probability of success in a Phase 3 Over 20 leading cancer centers in th

  19. Slide 19: I-SPY Launches New Study Arm with Oral Paclitaxel

    I-SPY 2 Launches New Study Arm with Oral Paclitaxel In Combination with GSK’s dostarlimab (PD-1 Antibody) Goal of Study: Evaluate the safety and efficacy of Oral Paclitaxel in combination with dostarlimab +/- carboplatin in the neoadjuvant breast cancer setting Primary Objective: Determine whether t

  20. Slide 20: Expanding Portfolio of Novel Cancer Therapeutics

    Expanding Portfolio of Novel Cancer Therapeutics Being developed by Axis Therapeutics, a joint venture between Athenex and Xiangxue Life Sciences (XLifeSc) FDA allowed the U.S. IND for TCRT-ESO-A2*, targeting solid tumors that are NY-ESO-1 positive in HLA-A*02:01 positive patients TCR-T Immunotherap

  21. Slide 21: Klisyri for Actinic Keratosis

    Klisyri for Actinic Keratosis Two Phase III Pivotal Studies in the U.S. Completed • Double-blind, vehicle-controlled, randomized, parallel group, multicenter • Enrolled 351 subjects in 31 U.S. sites per study (N=702) Efficacy Results KX01-AK-003 KX01-AK-004 % of Subjects in ITT Tirbanibulin Vehicle

  22. Slide 22: Actinic Keratosis (AK) Market Opportunity Is Significant

    Actinic Keratosis (AK) Market Opportunity Is Significant Actinic Keratosis Market Opportunity ◼ Common pre-cancerous skin condition characterized by scaly crusty skin lesions due to over exposure to the sun ◼ An estimated 10-15% of AK cases progress to cancer if left untreated 1 ◼ Estimates suggest

  23. Slide 23: Financial Snapshot

    Financial Snapshot Revenue for the nine-month period ended September 30, 2020 $122.6 million • Product sales, net $83.5 million • License and other revenue $39.1 million Cash, cash equivalents, restricted cash and short-term $242.1 million investments as of September 30, 2020 Potential gross proceed

  24. Slide 24: Deep Pipeline of Potentially Transformative Therapies

    Deep Pipeline of Potentially Transformative Therapies Athenex's Pipeline (as of Jan. 11, 2021) Status Licensing Partner(s) Drug Candidate and Program Pre-clinical Phase I Phase II Phase III Regulatory U.S. & EU RoW Metastatic breast cancer PDUFA Date 2/28/21 Monotherapy Angiosarcoma 1 Oral paclitaxe

  25. Slide 25: Management Team with Deep Pharma & Biotech Experience

    Management Team with Deep Pharma & Biotech Experience Led the Development of Many Global Drugs Johnson Lau MBBS, MD, FRCP Jeff Yordon Rudolf Kwan MBBS, MRCP Chief Executive Officer, Chairman Chief Operating Officer Chief Medical Officer 25+ years experience 45+ years experience 30+ years experience

  26. Slide 26: Our goal is to become a global leader in bringing innovative cancer treatments

    Our goal is to become a global leader in bringing innovative cancer treatments to the market and improving health outcomes NASDAQ:ATNX www.athenex.com

Athenex — Investor Presentation (January 2021) on 6ix